BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Oncology Therapeutics awarded an inducement grant on October 10, 2026 for one September hire under its 2025 Inducement Plan. The award consists of non-qualified stock options to purchase 90,000 shares at an exercise price of $3.31, vesting 1/4 on the first anniversary of start and monthly over 36 months thereafter.
Key figures
- Exercise price
- 3.31
- Inducement options shares
- 90000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.